News Headlines

  1. NANOBIOTIX Announces Positive Phase II/III Topline Data In Soft Tissue Sarcoma With NBTXR3
    6/21/2018

    NANOBIOTIX, a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced recently positive topline results of the Phase II/III act.in.sarc trial evaluating NBTXR3 in Soft Tissue Sarcoma (STS).

  2. Syneos Health And Elligo Announce Strategic Collaboration To Advance Clinical Research For Real-World Patients
    6/21/2018

    Syneos Health, the only fully integrated biopharmaceutical solutions organization, and Elligo Health Research, the only platform that brings clinical research direct to clinical health care, are entering a strategic collaboration to mobilize a system of accelerated research to reach real-world patients.

  3. MediWound Expands Its NexoBrid® Phase 3 Children Innovation Debridement Study (CIDS) To The U.S.
    6/19/2018

    MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the expansion of its NexoBrid Phase 3 Children Innovation Debridement Study (CIDS) to United States burn centers, following approval of the study protocol by the U.S. Food and Drug Administration (FDA) and site Institutional Review Boards (IRB).

  4. Sol-Gel Technologies Initiates Pivotal Phase III Clinical Program For Papulopustular Rosacea
    6/18/2018

    Sol-Gel Technologies Ltd. (NASDAQ:SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced dosing of the first subject in the pivotal Phase III clinical program evaluating the safety and efficacy of Epsolay® (formerly VERED) in subjects with papulopustular rosacea (also known as subtype II rosacea), a chronic, inflammatory skin condition that most often affects the face.

  5. Agios Announces Initiation Of Global Phase 3 Trial (ACTIVATE) Of AG-348 In Adults With Pyruvate Kinase Deficiency Who Are Not Regularly Transfused
    6/18/2018

    Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the initiation of the Phase 3 ACTIVATE trial evaluating AG-348, a first-in-class, selective, small molecule activator of the pyruvate kinase-R (PKR) enzyme.

  6. Certara Supports The Not-For-Profit Biotechnology Company Medicines Development For Global Health (MDGH) On The FDA New Drug Approval Of Moxidectin For The Treatment Of River Blindness (Onchocerciasis), A Neglected Tropical Disease
    6/15/2018

    Certara, the global leader in model-informed drug development, regulatory science, market access and real-world evidence services, recently celebrated an important milestone for its public health drug development and treatment consulting portfolio.

  7. MD Anderson, Houston Methodist Scientists Detect New Ovarian Cancer Target
    6/13/2018

    Researchers at Houston Methodist Research Institute and The University of Texas MD Anderson Cancer Center have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer.

  8. Immune-Based Gene Therapy Candidates Should Prevail In Oncology, Says GlobalData
    6/13/2018

    Gene therapy combines a reduced treatment duration with a higher chance of cure unlike conventional oncology treatments such as chemotherapy.

  9. OncoMed Doses First Patient In Phase 1b Portion Of Anti-TIGIT Clinical Trial
    6/13/2018

    OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the first patient has been dosed in the company’s Phase 1b portion of the Phase 1a/1b clinical trial of anti-TIGIT (OMP-313M32) in combination with anti-PD1 (nivolumab).

  10. Montrium Announces Plans For Full Adoption Of The New Reference Model eTMF Exchange Mechanism Standard
    6/12/2018

    Montrium, industry leading provider of cloud-based collaborative and compliant document and quality management system, announced recently this month it will be fully compliant with the TMF Reference Model Version 1.0 of the eTMF-EMS (eTMF Exchange Mechanism Standard).